Weatherly Asset Management L. P. Trims Stock Position in Eli Lilly and Company (NYSE:LLY)

Weatherly Asset Management L. P. trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 298,393 shares of the company's stock after selling 4,990 shares during the period. Eli Lilly and Company makes up about 18.7% of Weatherly Asset Management L. P.'s portfolio, making the stock its largest holding. Weatherly Asset Management L. P.'s holdings in Eli Lilly and Company were worth $173,939,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. JGP Wealth Management LLC grew its holdings in Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company's stock worth $1,074,000 after acquiring an additional 16 shares during the last quarter. Cassia Capital Partners LLC raised its holdings in Eli Lilly and Company by 1.8% during the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company's stock worth $511,000 after buying an additional 17 shares during the last quarter. Walkner Condon Financial Advisors LLC raised its holdings in Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company's stock worth $334,000 after buying an additional 17 shares during the last quarter. Patton Albertson Miller Group LLC raised its holdings in shares of Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company's stock valued at $335,000 after purchasing an additional 17 shares during the last quarter. Finally, Valley Wealth Managers Inc. raised its holdings in shares of Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company's stock valued at $688,000 after purchasing an additional 17 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now directly owns 99,488,598 shares of the company's stock, valued at approximately $64,177,109,911.86. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 133,785 shares of company stock worth $86,537,034 in the last quarter. Corporate insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Erste Group Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an "overweight" rating in a report on Friday, March 15th. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an "overweight" rating in a report on Friday, February 16th. DZ Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Finally, Truist Financial reissued a "buy" rating and set a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $728.05.

Eli Lilly and Company Stock Down 1.0 %

Shares of LLY traded down $7.95 during mid-day trading on Friday, hitting $751.64. 2,495,037 shares of the company traded hands, compared to its average volume of 2,285,401. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78. The business has a 50 day moving average of $761.77 and a 200 day moving average of $654.08. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $714.18 billion, a PE ratio of 129.59, a price-to-earnings-growth ratio of 1.65 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the prior year, the firm posted $2.09 EPS. The business's quarterly revenue was up 28.1% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 12.46 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.